Clinuvel Pharmaceuticals LimitedASX: CUV

CLINUVEL date of Annual General Meeting

· Issued by Clinuvel Pharmaceuticals Limited via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Clinuvel Pharmaceuticals Limited has announced the date for its Annual General Meeting, scheduled for early November. The notice includes details about the closing date for director nominations, which is set for late September. The company focuses on developing therapies for genetic and dermatological disorders, particularly through melanocortin peptides. Clinuvel's lead therapy, SCENESSE®, is approved for use in several countries as a photoprotective drug.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/clinuvel-date-of-annual-general-meeting

Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27

Release

A S X A N N O U N C E M E N T ASX: CUV | Nasdaq: CUVL | Börse Frankfurt: UR9 ASX Announcement PAGE 1 OF 2 CLINUVEL date of Annual General Meeting Melbourne / Singapore – 18 September 2026 – CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today provides notice that its Annual...

Clinuvel Pharmaceuticals Limited on 6ix

Earlier from Clinuvel Pharmaceuticals

Later from Clinuvel Pharmaceuticals

All Clinuvel Pharmaceuticals news releases